gt103
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2020 (NCT04314089)
Timeline
Indications
Mechanism of action
- Complement factor HINHIBITOR
CFH inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07017829 | Phase 2 | Dec 1, 2025 | State University of New York, Buffalo |
| NCT05617313 | Phase 2 | Dec 31, 2022 | Duke University, Grid Therapeutics, Merck |
| NCT04314089 | Phase 1 | May 31, 2020 | Duke University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Grid Therapeutics | For profit | 1 | 1 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1